Plasmodium hepatic stage (Schizont and Hypnozoite) (EE stage)

The hepatic stage of the Plasmodium parasite, encompassing both actively replicating schizonts and dormant hypnozoites, represents a critical phase of the malaria life cycle within host hepatocytes (CDC, 2020). While hepatic schizonts lead to the initial symptomatic blood-stage infection, hypnozoites—unique to Plasmodium vivax and Plasmodium ovale—can remain quiescent for weeks or years, causing clinical relapses upon reactivation (White et al., 2014). Targeting these stages is essential for achieving a 'radical cure' and preventing the transmission cycle of relapsing malaria (WHO, 2023). Because the specific molecular pathways governing hypnozoite dormancy are not fully defined, drug discovery frequently relies on phenotypic screening to identify compounds with hypnozoitocidal activity (Gamo et al., 2010). Currently, 8-aminoquinolines like primaquine and tafenoquine are the primary therapeutic agents, though their use is strictly limited by the risk of severe hemolysis in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency (FDA, 2018).

Other names

Exo-erythrocytic stageLiver stage malariaDormant malaria parasiteP. vivax hypnozoiteHepatic schizont

Drugs targeting this phenotypic stage typically act by inducing oxidative stress, disrupting parasite mitochondrial electron transport, or inhibiting parasite-specific metabolic pathways required for survival and reactivation from dormancy (Baird, 2019; FDA, 2018).